With 0.68 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.46 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $29.29 whereas the lowest price it dropped to was $25.835. The 52-week range on UPB shows that it touched its highest point at $26.99 and its lowest point at $5.14 during that stretch. It currently has a 1-year price target of $49.25. Beta for the stock currently stands at 1.87.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of UPB was up-trending over the past week, with a rise of 12.79%, but this was up by 22.26% over a month. Three-month performance surged to 72.63% while six-month performance rose 212.69%. The stock gained 75.36% in the past year, while it has gained 61.97% so far this year. A look at the trailing 12-month EPS for UPB yields -2.28 with Next year EPS estimates of -3.17. For the next quarter, that number is -0.71. This implies an EPS growth rate of 53.56% for this year and -22.29% for next year.
Float and Shares Shorts:
At present, 54.00 million UPB shares are outstanding with a float of 23.46 million shares on hand for trading. On 2025-11-14, short shares totaled 2.99 million, which was 554.0 higher than short shares on 1760486400. In addition to Dr. E. Rand Sutherland M.D., M.P.H., MPH as the firm’s CEO & Director, Mr. Michael Paul Gray CPA, MBA serves as its CFO & COO.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, UPB reported revenue of $683000.0 and operating income of -$37834000.0. The EBITDA in the recently reported quarter was -$37788000.0 and diluted EPS was -$0.63.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With UPB analysts setting a high price target of 75.0 and a low target of 35.0, the average target price over the next 12 months is 47.8. Based on these targets, UPB could surge 160.15% to reach the target high and rise by 21.4% to reach the target low. Reaching the average price target will result in a growth of 65.8% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$5.04023 being high and -$10.17381 being low. For UPB, this leads to a yearly average estimate of -$8.02704.
